Results-Conversion to normal sinus rhythm was similar in both groups (TAP 8111, DCC 9/10, p = 0-31). Arrhythmias after cardioversion including third degree heart block and nonsustained ventricular tachycardia were more frequent in the DCC group (TAP 0/11, DCC 6110, p = 0.02). Conclusion-Transoesophageal atrial pacing with an easily swallowed pill electrode is safe, well tolerated, and is as efficacious as DCC for refractory atrial flutter. (Br Heartj 1993;69:530-535) Cardiology Division,
The closeness of the distal oesophagus to the atria of the heart has been used to record atrial electrocardiograms since 1906, when Max Cremer passed a 10 x 15 cm electrode into the throat of a professional sword swallower. ' Transoesophageal electrodes have been useful for differentiating supraventricular tachycardia from ventricular tachycardia, for defining mechanisms of supraventricular tachycardia, in the measurement of interatrial conduction times, and most recently, for delivery of electrical stimuli to the atria for diagnostic and therapeutic purposes.
Atrial flutter is a relatively common supraventricular tachyarrhythmia. Because of haemodynamic instability encountered with this arrhythmia, it is desirable to convert atrial flutter to normal sinus rhythm. Although medical treatment with agents that prolong the myocardial refractory period are usually attempted, these agents generally fail to end the arrhythmia.2 Direct current cardioversion (DCC) offers a highly effective technique to end atrial flutter; however, this method requires light anaesthesia and may be poorly tolerated by a significant proportion of patients with atrial flutter, particularly those patients treated with digoxin to control the ventricular response rate.'-To end atrial flutter by rapid overdrive atrial pacing is an alternative to DCC. Rapid pacing from the oesophagus is feasible and has been used to end atrial flutter." Initial studies of transoesophageal atrial pacing (TAP) used large electrodes designed for transvenous pacing and that required nasal or oral intubation. A recent innovation has been the development of an easily swallowed oesophageal pill electrode.9 Clinical evaluation of this has been limited to paediatric'0 and unselected adult populations.1' This report presents the results of a prospective, randomised clinical trial comparing TAP with DCC to end atrial flutter in a selected population of patients in whom appropriate antiarrhythmic medication has failed.
Patients and methods

PATJENTS
All patients referred to the cardiology consultation service at the Naval Hospital, Oakland, California with refractory atrial flutter were prospectively evaluated for entry into the trial. Twenty four consecutive patients with refractory atrial flutter were evaluated. Two patients were excluded because of their inability to give informed consent and one patient was excluded because of oesophageal stricture that impared the patient's ability to swallow the pill electrode. Patients were also excluded if they had electrocardiographic evidence of Wolffe-Parkinson-White syndrome or were haemodynamically unstable and considered to require immediate DCC. These criteria, however, were not found in our consecutive series of patients. Atrial (fig 3) , atrial fibrillation (fig 4) Mean left atrial dimension was 44 0 (6*1) cm (range 28-52).
The mean depth of the transoesophageal pill electrode at which cardioversion was attempted was 34-3 (1-7) (range 32-38) cm.
Transoesophageal atmial pacing Pacing energies that produced cardioversion ranged from 20-40 mA, with a mean of 29 1 (8-3) mA. In seven patients in the DCC group, a single 25 J shock produced cardioversion. Two patients required a second cardioversion at 25 J. One patient failed to be converted to normal sinus rhythm after five cardioversions with a final energy of 200 J. Table 2 shows the comparability between groups. Both groups were comparable with regards to age, sex, atrial rate, left atrial dimension, presence of ASCAD, and concurrent use of digoxin and class IA antiarrhythmic agents. Duration of atrial flutter was indeterminate in three patients in the DCC group and two patients in the TAP group. A trend towards increased duration of atrial flutter at the time of electrical cardioversion was noticed in the TAP group, but this was not statistically significant (TAP 7-2 (4 8); DCC 5-3 (3 9) days, p = 0 09).
MORBIDITY OR MORTALITY
There were no deaths in this study. Conversion to normal sinus rhythm was seen in eight of 11 (72 7%) patients in the TAP group compared with nine of 10 (90%) patients in the DCC group (p = 0-31). Six patients in the TAP group showed a transient period of atrial fibrillation before conversion to normal sinus rhythm. Transient epigastric burning was noted in all patients who underwent TAP. The burning sensation was limited to periods of pacing and was generally well tolerated for short periods (less than two minutes). Prolonged epigastric burning or discomfort after pacing was not found. Non- No incidences of cardiac chest pain, chest burns, or dysphagia were found. Arrhythmias after cardioversion were seen in six of 10 patients after DCC but not after TAP (p < 0-01). The arrhythmias were benign (frequent, multifocal, or coupled) ventricular premature beats in four patients and transient second degree heart block in two patients. One patient developed a 10 s episode of nonsustained ventricular tachycardia that was treated with a short course of intravenous lidocaine. One patient developed complete heart block and prolonged hypotension that was successfully treated with cardiopulmonary resuscitation and atropine. The serum digoxin concentration was subsequently found to be slightly raised (beyond the therapeutic range) to 2-3 jug/dl in this patient.
Discussion
The efficacy of rapid atrial pacing to end atrial flutter is well established. An analysis of the major clinical trials involving transvenous pacing shows a cumulative success rate of 82% (range 55%-100%).14 In the immediate period after open heart surgery, rapid atrial pacing through wire electrodes implanted on the atrial epicardium is considered to be the treatment of choice, with a reported efficacy of 90%_100%.15 Although highly successful, direct atrial stimulation is limited by its invasive nature, which requires sterile precautions, fluoroscopy, cardiac catheterisation, and considerable operator expertise. Transoesophageal atrial pacing is a simple and noninvasive technique with efficacy similar to transvenous pacing. The use of an oesophageal electrode to pace the heart was first reported by Zoll in 1952, who used the electrode for ventricular pacing. 16 Since then, several clinical trials have investigated TAP as a technique to end atrial arrhythmias. Table 3 Gallagher et al performed strength-duration curves that showed that oesophageal current threshold decreased progressively as pulse duration was increased to the limit of the stimulator (9-9 ms).6 In our clinical trial, we chose to maintain pulse width at the stimulator limit of 10 ms. The experience of Chung et al, who used pulse widths up to 25 ms, suggest, however, that increases beyond 10 ms may improve the rates of ending atrial flutter.7 Theoretically, increased pulse widths might result in higher rates of inadvertent ventricular capture. This event has been described only rarely, however, and was not found in the present study. A sensation of transient epigastric burning, similar to our findings, has been reported to accompany TAP in a high percentage of cases. With a silicone insulated permanent bipolar pacing lead, Chung et al reported that 23% (9/39) of patients require intravenous sedation during TAP.7 No patients undergoing TAP in our study required intravenous sedation and most patients agreed that they would undergo the procedure again under similar circumstances. An advantage of TAP was that intravenous sedation was found to be unnecessary whereas DCC requires light anaesthesia and the presence of a trained anaesthesiologist.
Arrhythmias after cardioversion in digitalised patients undergoing DCC have been previously reported to be raised. 19 Our results support these findings. Although most of the arrhythmias found were of a benign nature, 20% (2/10) of patients in the DCC group experienced a potentially life threatening arrhythmia. Arrhythmias probably result from digitalis cardiotoxicity.20 Subsequent treatment of these arrhythmias should avoid additional direct current shocks as ventricular fibrillation may result.
Although several potential mechanisms for atrial flutter have been described, most clinical and experimental evidence supports a leading circle model of obstacle reentry. [21] [22] [23] This model uses the concept of a fully excitable gap that exists between the crest of the circulating wavefront and its tail of refractory myocardium and explains the reproducible end of atrial flutter with entrainment and rapid atrial pacing. The end of reentrant tachycardias by appropriately timed pacing stimuli occurs due to invasion of the reentrant circuit by the externally induced impulses. The pacing stimuli enter the circuit at the excitable gap, thereby rendering this tissue refractory to the circulating wavefront. Also, pacing stimuli may occur during the atrial vulnerable period inducing an atrial R on T phenomenon and fibrillation. Such a process may account for the frequency of transient atrial fibrillation found in our study. Class IA antiarrhythmic agents greatly decrease myocardial conduction velocity and to a lesser degree prolong the myocardial refractory period.24 The net effect in atrial flutter is to prolong the excitable gap. This may increase -the efficacy of rapid atrial pacing by facilitating invasion of the pacing stimuli into a widened excitable gap,25 and probably has contributed to the favourable results found in this study.
Our results show that TAP with a pill electrode is safe, well tolerated, and is as efficient as DCC for refractory atrial flutter. Class IA antiarrhythmic drugs probably facilitate TAP and should be considered adjunctive agents to the technique. Transoesophageal atrial pacing is especially well suited to patients taking digoxin or when digitalis toxicity is a consideration. Transoesophageal atrial pacing may also be considered in cases where DCC is not readily available or when light anaesthesia is contraindicated. The technique may also be combined with transoesophageal electrocardiography and used for diagnostic purposes in patients with an indeterminate rhythm on a surface electrocardiogram.
